Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-102.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.02 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -159.93% |
| Return on Assets (Trailing 12 Months) | -82.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.65 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.44 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 64.56M |
| Free Float | 56.70M |
| Market Capitalization | $255.02M |
| Average Volume (Last 20 Days) | 5.27M |
| Beta (Past 60 Months) | 1.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.18% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |